PEDIATRICS Vol. 101 No. 2 February 1998, pp. 214-220
A Randomized Comparative Trial of Stavudine (d4T) Versus Zidovudine (ZDV, AZT) in Children With Human Immunodeficiency Virus Infection
Received Feb 13, 1997; accepted Jul 1, 1997.
,
,,
From the * Department of Pediatrics, Baylor College of Medicine
and Texas Children's Hospital, Houston, Texas; Department of
Pediatrics, Tulane University Medical School, New Orleans, Louisiana;
§ Center for Biostatistics in AIDS Research, Harvard School of Public
Health, Boston, Massachusetts; Pediatric ACTG Operations Center,
Rockville, Maryland; ¶ Division of AIDS, National Institute of Allergy
and Infectious Diseases, Bethesda, Maryland; # Department of Pediatrics,
Duke University Medical Center, Durham, North Carolina; ** Department of
Neurosciences, University of California School of Medicine, San Diego,
California; Department of Pediatrics, Children's Hospital of Los
Angeles and the University of Southern California School of Medicine,
Los Angeles, California; §§ Department of Pediatrics, Children's
Memorial Hospital and Northwestern University Medical School, Chicago,
Illinois; and || Department of Pediatrics, St Joseph's Hospital and
Medical Center, Newark, New Jersey.
Objectives. To compare the safety and tolerance of stavudine (d4T) versus zidovudine (ZDV, AZT) in symptomatic human immunodeficiency virus-infected children 3 months to 6 years of age.
Methods. In an initially double-blind trial, 212 evaluable human immunodeficiency virus-infected children who had received no more than 6 weeks of previous antiretroviral therapy were randomized to receive either d4T (1 mg/kg orally every 12 hours, maximum 40 mg orally every 12 hours) or zidovudine (180 mg/m2 orally every 6 hours, maximum 200 mg orally every 6 hours). The study was unblinded after a median follow-up period of 6.3 months; median follow-up at study closure was 17.3 months. Tolerance, safety, disease progression, and immunologic responses were evaluated.
Results. The patient population was young (median age, 1.2 years; range, 0.3 to 6.4 years), with a median baseline CD4+ lymphocyte count of 965 cells/µL (range, 18 to 4238 cells/µL). Neutropenia <400/µL occurred significantly more commonly among zidovudine recipients (1-year event rates of 20% both up to the time of unblinding and throughout the entire study) than among children receiving d4T (1-year event rates of 5% up to the time of unblinding and 6% throughout the entire study). In exploratory activity analyses using all data collected until study closure, children treated with d4T showed consistently greater positive changes from baseline in weight-for-age-and-gender z scores. As expected in this population of young children, median absolute CD4+ lymphocyte counts decreased in both treatment groups. Smaller changes from baseline were noted among d4T recipients.
Conclusions. In children between the ages of 3 months and 6 years, d4T and zidovudine are largely comparable in terms of safety and tolerance. Neutropenia occurs significantly less commonly among children treated with d4T. There was evidence that weight gain and absolute CD4+ lymphocyte counts were better maintained in children receiving d4T.
Key words: stavudine, zidovudine, HIV infection, infant or child.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  G. M. Lee, S. L. Gortmaker, K. McIntosh, M. D. Hughes, J. M. Oleske, and Pediatric AIDS Clinical Trials Group Protocol 219C Quality of Life for Children and Adolescents: Impact of HIV Infection and Antiretroviral Treatment Pediatrics, February 1, 2006; 117(2): 273 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kaul, M. W. Kline, J. A. Church, and L. M. Dunkle Determination of Dosing Guidelines for Stavudine (2',3'-Didehydro-3'-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., March 1, 2001; 45(3): 758 - 763. [Abstract] [Full Text]
|
|
|
|
|
|
X. Sáez-Llorens, R. P. Nelson Jr, P. Emmanuel, A. Wiznia, C. Mitchell, J. A. Church, J. Sleasman, R. Van Dyke, C. G. Richardson, A. Cutrell, et al. A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children Pediatrics, January 1, 2001; 107(1): 4e - 4. [Abstract] [Full Text]
|
|
|
|
|
|
M. W. Kline, R. B. Van Dyke, J. C. Lindsey, M. Gwynne, M. Culnane, C. Diaz, R. Yogev, R. E. McKinney Jr, E. J. Abrams, L. M. Mofenson, et al. Combination Therapy With Stavudine (d4T) Plus Didanosine (ddI) in Children With Human Immunodeficiency Virus Infection Pediatrics, May 1, 1999; 103(5): 62e - 62. [Abstract] [Full Text]
|
|
|
|
|
|
Antiretroviral Therapy and Medical Management of Pediatric HIV Infection Pediatrics, October 1, 1998; 102(4): 1005 - 1062. [Full Text]
|
|
